These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 25975377)
21. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255 [TBL] [Abstract][Full Text] [Related]
22. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value? Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788 [TBL] [Abstract][Full Text] [Related]
23. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. Rorive S; Maris C; Debeir O; Sandras F; Vidaud M; Bièche I; Salmon I; Decaestecker C J Neuropathol Exp Neurol; 2006 Aug; 65(8):794-807. PubMed ID: 16896313 [TBL] [Abstract][Full Text] [Related]
24. Role of gemistocytes in astrocytoma progression. Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164 [TBL] [Abstract][Full Text] [Related]
25. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. Appin CL; Brat DJ Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780 [TBL] [Abstract][Full Text] [Related]
26. Analysis of the IDH1 codon 132 mutation in brain tumors. Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363 [TBL] [Abstract][Full Text] [Related]
27. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311 [TBL] [Abstract][Full Text] [Related]
28. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Miyakawa A; Ichimura K; Schmidt EE; Varmeh-Ziaie S; Collins VP Br J Cancer; 2000 Feb; 82(3):543-9. PubMed ID: 10682663 [TBL] [Abstract][Full Text] [Related]
30. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489 [TBL] [Abstract][Full Text] [Related]
31. Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. Ohta T; Kim YH; Oh JE; Satomi K; Nonoguchi N; Keyvani K; Pierscianek D; Sure U; Mittelbronn M; Paulus W; Vital A; Yokoo H; McDonald K; Kleihues P; Nazaret N; Barbet F; Lachuer J; Ohgaki H J Neuropathol Exp Neurol; 2014 Oct; 73(10):908-15. PubMed ID: 25192052 [TBL] [Abstract][Full Text] [Related]
32. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161 [TBL] [Abstract][Full Text] [Related]
33. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301 [TBL] [Abstract][Full Text] [Related]
34. Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. Goeppert B; Schmidt CR; Geiselhart L; Dutruel C; Capper D; Renner M; Vogel MN; Zachskorn C; Zinke J; Campos B; Schmezer P; Popanda O; Wick W; Weller M; Meyermann R; Schittenhelm J; Harter PN; Simon P; Weichert W; Schirmacher P; Plass C; Mittelbronn M J Neuropathol Exp Neurol; 2013 Oct; 72(10):933-41. PubMed ID: 24042196 [TBL] [Abstract][Full Text] [Related]
35. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494 [TBL] [Abstract][Full Text] [Related]
36. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448 [TBL] [Abstract][Full Text] [Related]
37. The definition of primary and secondary glioblastoma. Ohgaki H; Kleihues P Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033 [TBL] [Abstract][Full Text] [Related]
39. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment. Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349 [TBL] [Abstract][Full Text] [Related]
40. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification]. Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]